5747s11485
NM_001199649.1 NM_001316342.1 NM_005607.4 NM_153831.3 XM_005251003.2 XM_005251012.2 XM_005251013.2 XM_006716608.2 XM_006716609.2 XM_006716610.2 XM_011517194.2 XM_017013651.1 XM_017013652.1 XM_017013653.1 XM_017013654.1 XM_017013655.1 XM_017013656.1 XM_017013657.1 XM_017013658.1 XM_017013659.1 XM_017013660.1 XM_017013661.1 XM_017013662.1 XM_017013663.1 XM_017013664.1 XM_017013665.1 XM_017013666.1 XM_017013667.1 XM_017013668.1 XM_017013669.1 XM_017013670.1 XM_017013671.1 XM_017013672.1 XM_017013673.1 XM_017013674.1 XM_017013675.1 XM_017013676.1 XM_017013677.1 XM_017013678.1 XM_017013679.1 XM_017013680.1 XM_017013681.1 XM_017013682.1 XM_017013683.1 XM_017013684.1 XM_017013685.1 XM_017013686.1 XM_017013687.1 XM_017013688.1 XM_017013689.1 XM_017013690.1
11%(+/-2% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00178587_m1]
HeLa cells were reverse transfected with 5nM gene-specific Silencer® Select siRNA or 5nM Silencer® Select Negative Control #2 siRNA. 48 hours post-transfection, gene expression analysis was performed using the TaqMan® Gene Expression Cells-to-CT Kit and appropriate TaqMan® Gene Expression Assays. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.